Infectious Disease Diagnostic Solutions

Rapid Immunoassay & RT-PCR COVID-19 Test and More



Rapid and accurate detection of COVID-19

- One of the earliest WHO EUL & FDA EUA
- Automated workflow for high throughput testing
- Trusted performance
- Uncompromised by COVID variants
- Multiplex assay for SARS CoV 2/ FluA FluB

Syndromic PCR Panels PMeasy™ Lab



Multiplex PCR Testing up to 18 targets

- Coming soon

- Optimal performance for syndromic testing
- Integrated system with DNA extraction & amplification
- User friendly design for decentralized testing

Rapid Immunoassay & RT-PCR Medium & Large-scale COVID Testing



Integrated, scalable automation solutions

- Integrated end to end automated workflow
- Fast TAT sample to result in 4 hr
- Flexible and scalable throughput
- Broad Compatibility: VTMs, thermocyclers, plate types, specimen tubes

Metagenomic Sequencing PMseq[™] mNGS Test



Pathogenic Microorganism sequencing PMseq[™] - Coming soon

- The ultimate solution to diagnostic odyssey
- Detection of unknown or novel pathogen(s) causing severe infection in respiratory tract, blood, CNS, fecal points
- Proven clinical utilities, simplified & sustainable workflows

Infectious Disease Diagnostic Solutions

BGI Offices

BGI Americas

One Broadway, 14th Floor Cambridge, MA 02142, USA

BGI Europe

Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark

BGI Asia

Building NO.7 BGI Park, No.21 Hongan 3rd Street, Yantian District, Shenzhen, China

BGI Australia

L6, CBCRC, 300 Herston Road, Herston, Brisbane, Queensland 4006, Australia

B

www.bgi.com/us info@bgi.com

Copyright ©BGI 2022. All trademarks are the property of BGI, or their respective owners.

* For Emergency Use Authorization Only | For In Vitro Diagnostic Use | Rx Only. In the United States: - This test has not been FDA cleared or approved; - This test has been authorized by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and - This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

This material contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Note, BGI's genetic testing products have not been cleared or approved by the US FDA and are not available in the USA. For Research Use Only.

Unless otherwise informed, all sequencers and sequencing reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium or Italy. Certain sequencing services are not available in USA and Hong Kong. Please contact a representative for regional availability. The company reserves the right of final interpretation.



@BGI Genomics